About FutureNeuro

 We aim to change the patient journey through research informed by the needs of both patients and neurologists. This includes developing rapid and accurate tools for diagnosis, the development of therapies to modify brain networks, technologies to enable patients to monitor their own health and well-being, and linking this to Ireland’s national imaging, diagnostics and eHealth infrastructure.

We are multi-disciplinary, inter-institutional and working with industry, patient organisations and the health service to transform the lives of patients in Ireland and worldwide.

We focus on epilepsy, a chronic brain disease-affecting people of all ages, and ALS (also known as motor neurone disease), a rare neurodegenerative disease, which can be viewed as a model of more common neurodegenerations in terms of shared pathomechanisms, clinical pathways and patient journey. This unique approach has proven a powerful strategy for discovery that, along with our underpinning technology platforms and national clinical network, allows us to scale to other neurological disorders. That process has begun, with research underway on Parkinson’s disease, Multiple Sclerosis and other rare neurological diseases.

FutureNeuro conducts research in three thematic areas:

Diagnostics: Provision of an accurate molecular diagnosis through the discovery of genetic and circulating biomarkers of disease and developing technology for their detection.

Therapeutics: Discovery of novel and disease-modifying treatments that target hyperexcitable and damaged brain networks, optimizing treatment and clinical trials.

eHealth: Delivery of proactive, personalised and precision patient management and the development of research-enabled healthcare systems and connected health solutions to improve care, enrich research and facilitate clinical trials.

We bring together the brightest research talent in neuroscience, clinical neurology, genetics, cell biology, materials chemistry and patient data analytics, led by our team of cross-intitutional principal investigators.